

AMENDMENTS**Amendments to the Claims**

- 1) (Currently amended) A method for extending the effective period during which tissue treated with a clostridial toxin is paralyzed comprising: ~~contacting said tissue with a composition comprising an agent able to prevent the neuroregenerative activity of a polypeptide selected from the group consisting of: IGF I, IGF II, ciliary neurotrophic factor, NT-3, NT-4, brain-derived neurotrophic factor, leukemia inhibitory factor, tenascin-C, ninjurin, neural cell adhesion molecule, and neural agrin~~
 - a) contacting said tissue with a composition comprising an agent able to prevent the expression of a neurotrophic polypeptide, and
 - b) contacting said tissue with a clostridial neurotoxin,wherein neural sprouting in said treated tissue is inhibited.
- 2) (Currently amended) The method of claim 1 wherein ~~said contacting step a)~~ occurs at the same time as said tissue is treated with said clostridial toxin.
- 3) (Currently amended) The method of claim 1 wherein ~~said contacting step a)~~ occurs prior to treatment of said tissue with said clostridial toxin.
- 4) (Original) The method of claim 1 wherein said clostridial toxin comprises BoNT.
- 5) (Original) The method of claim 1 wherein said clostridial toxin comprises BoNT/A.
- 6) (Original) The method of claim 1 wherein said agent is selected from the group consisting of:
 - a) an antibody able to selectively bind said polypeptide,

- b) a competitive inhibitor of said polypeptide,
 - c) a compound able to selectively prevent the expression of a gene encoding said polypeptide,
 - d) a binding protein other than an antibody, and
 - e) a ribozyme,
 - f) a nucleic acid encoding an inactive growth factor receptor able to bind said growth factor.
- 7) (Original) The method of claim 6 wherein said agent is an antibody able to selectively bind said polypeptide.
- 8) (Original) The method of claim 6 wherein said agent is a competitive inhibitor of said polypeptide.
- 9) (Original) The method of claim 6 wherein said agent is a compound able to prevent the expression of a gene encoding said polypeptide.
- 10) (Original) The method of claim 6 wherein said agent is a binding protein other than an antibody.
- 11) (Original) The method of claim 9 wherein said polypeptide is selected from the group consisting of IGF I and IGF II, and said binding protein is selected from the group consisting of IGF-BP4 and IGF-BP5.
- 12) (Original) A method for stimulating the outgrowth of neural sprouts from damaged neural tissue comprising: contacting said tissue with a composition comprising a polypeptide which comprises a neurotropically active domain derived from an agent selected from the group consisting of IGF I, IGF II, ciliary neurotrophic factor, NT-3, NT-

4, brain-derived neurotrophic factor, leukemia inhibitory factor, tenascin-C, ninjurin, neural cell adhesion molecule, and neural agrin.

13) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises IGF I.

14) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises IGF II.

15) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises NT-3.

16) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises ciliary neurotrophic factor.

17) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises NT-3.

18) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises NT-4.

19) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises brain-derived neurotrophic factor.

20) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises leukemia inhibitory factor.

21) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises tenascin-C.

22) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises ninjurin.

23) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises neural-cell adhesion molecule.

24) (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises neural agrin.

25. (New) The method of claim 1 wherein said polypeptide is selected from the group consisting of: IGF I, IGF II, ciliary neurotrophic factor, NT-3, NT-4, brain-derived neurotrophic factor, leukemia inhibitory factor, tenascin-C, ninjurin, neural cell adhesion molecule, and neural agrin.